Oadi N. Shrateh , Kanwal Ashok Kumar , Areesha Jawed , Muhammad Hamza Shuja , Hammad Ur Rehman Shamsi , Mashhour Naasan
{"title":"比较吡哆醇与多巴胺能激动剂(卡麦角林和溴隐亭):揭示抑制泌乳的策略--临床试验的系统回顾。","authors":"Oadi N. Shrateh , Kanwal Ashok Kumar , Areesha Jawed , Muhammad Hamza Shuja , Hammad Ur Rehman Shamsi , Mashhour Naasan","doi":"10.1016/j.jogoh.2024.102783","DOIUrl":null,"url":null,"abstract":"<div><p>This systematic review aims to evaluate the efficacy and safety of Pyridoxine compared to Dopaminergic agonists (cabergoline and bromocriptine) in post-partum lactation inhibition. Cochrane Central, PubMed/MEDLINE, Cochrane Central, ScienceDirect, ClinicalTrials.gov, Web of Science, CINAHL and Google Scholar, covering the period from inception to November 2023. Additionally, the bibliographies of included articles and previous meta-analyses were screened for any relevant articles. The systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The outcomes of interest encompassed inhibition of lactation, breast pain/tenderness, breast engorgement, milk secretion, fever, mastitis, prolactin level and adverse events related to pyridoxine, cabergoline and bromocriptine. Methodological quality assessment was conducted using the Cochrane risk of bias assessment tool for rigorous evaluation. Three clinical trials assessed the effectiveness of pyridoxine and dopaminergic agents (cabergoline and bromocriptine) for lactation inhibition. It was assessed by using different assessment methods such as a scale for milk secretion, serum prolactin levels, and questionnaires for assessing breast engorgement, breast pain, and milk leakage. On the global assessment of the therapeutic efficacy of dopaminergic agents, it was found that there was significant inhibition of lactation as compared to pyridoxine (<em>p</em> < 0.001). In conclusion, this systematic review contributes significant insights into lactation inhibition interventions. Dopaminergic agonists, specifically cabergoline and bromocriptine, stand out as more effective and tolerable choices compared to Pyridoxine. These findings provide a foundation for informed clinical decisions and underscore the need for careful consideration of lactation inhibition strategies in diverse clinical contexts.</p></div>","PeriodicalId":15871,"journal":{"name":"Journal of gynecology obstetrics and human reproduction","volume":"53 6","pages":"Article 102783"},"PeriodicalIF":1.7000,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468784724000618/pdfft?md5=80a2fd5c65927c8525da8444af194ece&pid=1-s2.0-S2468784724000618-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials\",\"authors\":\"Oadi N. Shrateh , Kanwal Ashok Kumar , Areesha Jawed , Muhammad Hamza Shuja , Hammad Ur Rehman Shamsi , Mashhour Naasan\",\"doi\":\"10.1016/j.jogoh.2024.102783\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This systematic review aims to evaluate the efficacy and safety of Pyridoxine compared to Dopaminergic agonists (cabergoline and bromocriptine) in post-partum lactation inhibition. Cochrane Central, PubMed/MEDLINE, Cochrane Central, ScienceDirect, ClinicalTrials.gov, Web of Science, CINAHL and Google Scholar, covering the period from inception to November 2023. Additionally, the bibliographies of included articles and previous meta-analyses were screened for any relevant articles. The systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The outcomes of interest encompassed inhibition of lactation, breast pain/tenderness, breast engorgement, milk secretion, fever, mastitis, prolactin level and adverse events related to pyridoxine, cabergoline and bromocriptine. Methodological quality assessment was conducted using the Cochrane risk of bias assessment tool for rigorous evaluation. Three clinical trials assessed the effectiveness of pyridoxine and dopaminergic agents (cabergoline and bromocriptine) for lactation inhibition. It was assessed by using different assessment methods such as a scale for milk secretion, serum prolactin levels, and questionnaires for assessing breast engorgement, breast pain, and milk leakage. On the global assessment of the therapeutic efficacy of dopaminergic agents, it was found that there was significant inhibition of lactation as compared to pyridoxine (<em>p</em> < 0.001). In conclusion, this systematic review contributes significant insights into lactation inhibition interventions. Dopaminergic agonists, specifically cabergoline and bromocriptine, stand out as more effective and tolerable choices compared to Pyridoxine. These findings provide a foundation for informed clinical decisions and underscore the need for careful consideration of lactation inhibition strategies in diverse clinical contexts.</p></div>\",\"PeriodicalId\":15871,\"journal\":{\"name\":\"Journal of gynecology obstetrics and human reproduction\",\"volume\":\"53 6\",\"pages\":\"Article 102783\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2468784724000618/pdfft?md5=80a2fd5c65927c8525da8444af194ece&pid=1-s2.0-S2468784724000618-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of gynecology obstetrics and human reproduction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468784724000618\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gynecology obstetrics and human reproduction","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468784724000618","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
本系统综述旨在评估吡哆醇与多巴胺能激动剂(卡麦角林和溴隐亭)相比在产后泌乳抑制方面的有效性和安全性。研究范围包括 Cochrane Central、PubMed/MEDLINE、Cochrane Central、ScienceDirect、ClinicalTrials.gov、Web of Science、CINAHL 和 Google Scholar,时间跨度从开始到 2023 年 11 月。此外,还对纳入文章的参考书目和以往的荟萃分析进行了筛选,以查找相关文章。系统综述根据《科克伦干预措施系统综述手册》进行。研究结果包括泌乳抑制、乳房疼痛/触痛、乳房充血、乳汁分泌、发热、乳腺炎、催乳素水平以及与吡哆醇、卡麦角林和溴隐亭相关的不良反应。方法学质量评估采用 Cochrane 偏倚风险评估工具进行严格评估。三项临床试验评估了吡哆醇和多巴胺能药物(卡麦角林和溴隐亭)抑制泌乳的效果。评估采用了不同的评估方法,如乳汁分泌量表、血清催乳素水平以及评估乳房充血、乳房疼痛和乳汁渗漏的问卷。在对多巴胺能药物的疗效进行全面评估时发现,与吡哆醇相比,多巴胺能药物能显著抑制泌乳(p < 0.001)。总之,本系统综述为抑制泌乳的干预措施提供了重要见解。与吡哆醇相比,多巴胺能激动剂,特别是卡麦角林和溴隐亭,是更有效、更耐受的选择。这些研究结果为做出明智的临床决定奠定了基础,并强调了在不同的临床环境中仔细考虑泌乳抑制策略的必要性。
Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials
This systematic review aims to evaluate the efficacy and safety of Pyridoxine compared to Dopaminergic agonists (cabergoline and bromocriptine) in post-partum lactation inhibition. Cochrane Central, PubMed/MEDLINE, Cochrane Central, ScienceDirect, ClinicalTrials.gov, Web of Science, CINAHL and Google Scholar, covering the period from inception to November 2023. Additionally, the bibliographies of included articles and previous meta-analyses were screened for any relevant articles. The systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. The outcomes of interest encompassed inhibition of lactation, breast pain/tenderness, breast engorgement, milk secretion, fever, mastitis, prolactin level and adverse events related to pyridoxine, cabergoline and bromocriptine. Methodological quality assessment was conducted using the Cochrane risk of bias assessment tool for rigorous evaluation. Three clinical trials assessed the effectiveness of pyridoxine and dopaminergic agents (cabergoline and bromocriptine) for lactation inhibition. It was assessed by using different assessment methods such as a scale for milk secretion, serum prolactin levels, and questionnaires for assessing breast engorgement, breast pain, and milk leakage. On the global assessment of the therapeutic efficacy of dopaminergic agents, it was found that there was significant inhibition of lactation as compared to pyridoxine (p < 0.001). In conclusion, this systematic review contributes significant insights into lactation inhibition interventions. Dopaminergic agonists, specifically cabergoline and bromocriptine, stand out as more effective and tolerable choices compared to Pyridoxine. These findings provide a foundation for informed clinical decisions and underscore the need for careful consideration of lactation inhibition strategies in diverse clinical contexts.
期刊介绍:
Formerly known as Journal de Gynécologie Obstétrique et Biologie de la Reproduction, Journal of Gynecology Obstetrics and Human Reproduction is the official Academic publication of the French College of Obstetricians and Gynecologists (Collège National des Gynécologues et Obstétriciens Français / CNGOF).
J Gynecol Obstet Hum Reprod publishes monthly, in English, research papers and techniques in the fields of Gynecology, Obstetrics, Neonatology and Human Reproduction: (guest) editorials, original articles, reviews, updates, technical notes, case reports, letters to the editor and guidelines.
Original works include clinical or laboratory investigations and clinical or equipment reports. Reviews include narrative reviews, systematic reviews and meta-analyses.